News
-
-
PRESS RELEASE
MIRA Pharmaceuticals Initiates Multiple Ascending Dose (MAD) Phase 1 Study of Oral Ketamir-2 and Selects Chemotherapy-Induced Neuropathic Pain as Lead Phase 2a Indication
MIRA Pharmaceuticals advances Ketamir-2 into Phase 2a clinical evaluation for chemotherapy-induced peripheral neuropathy with potential for FDA Fast Track status -
-
PRESS RELEASE
MIRA Pharmaceuticals Announces Oral Mira-55 Outperformed Injected Morphine in Normalizing Pain and Reducing Inflammation, Supporting Its Planned IND for Chronic Inflammatory Pain
MIRA Pharmaceuticals unveils groundbreaking preclinical data on pain relief & inflammation reduction with oral Mira-55, positioning itself in $70B non-opioid pain market -
-
PRESS RELEASE
MIRA Pharmaceuticals Closes Acquisition of SKNY Pharmaceuticals, Expands Pipeline with SKNY-1 for Obesity and Nicotine Addiction
MIRA Pharmaceuticals completes acquisition of SKNY Pharmaceuticals, strengthening financial position. SKNY-1 for obesity and smoking cessation, Ketamir-2 for neuropathic pain, and MIRA-55 for inflammatory pain -
-
PRESS RELEASE
MIRA Pharmaceuticals Announces Favorable Topline Results from Phase 1 SAD Study of Oral Ketamir-2, a Next-Generation Non-Scheduled Ketamine Analog
MIRA Pharmaceuticals announces positive Phase 1 results for oral candidate Ketamir-2, showing safe, well-tolerated, predictable absorption, and no CNS side effects -
-
PRESS RELEASE
MIRA Pharmaceuticals Reports Positive PTSD Data Demonstrating Ketamir-2 Restores Normalized Behavior in Stressed Animals
MIRA Pharmaceuticals advances Ketamir-2 in clinical trials for neuropathic pain and expands into neuropsychiatric disorders like PTSD, showing promising results in a PTSD model
